Pharmaceutical company Viatris (the sponsor) has notified us that supply constraints relating to Creon 25,000 unit and Creon 35,000 unit capsules will continue until 30 June 2026. This is due to an unexpected global increase in demand.
Viatris will continue to receive a regular supply of all strengths of Creon, but availability may be limited and may vary from one pharmacy to another during this period.
We ask that patients and pharmacies do not stockpile product so that the sponsor can distribute what is available fairly to meet everyone’s needs.
Creon (pancreatic extract) capsules are indicated for the treatment of pancreatic enzyme insufficiency, particularly in patients with cystic fibrosis, chronic pancreatitis and after gastrectomy/pancreatic surgery.
For more information for patients, pharmacists and prescribers, go to: About the shortage of Creon (pancreatic extract) capsules.
You can also check the Medicine Shortage Reports Database for updates about the situation.